BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 7756183)

  • 1. The positive and negative symptoms of schizophrenia: patterns of response to depot neuroleptic treatment.
    Martyns-Yellowe IS
    West Afr J Med; 1994; 13(4):200-3. PubMed ID: 7756183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clopenthixol and flupenthixol depot preparations in outpatient schizophrenics. I. A one year double-blind study of clopenthixol decanoate and flupenthixol palmitate.
    Dencker SJ; Lepp M; Malm U
    Acta Psychiatr Scand Suppl; 1980; 279():10-28. PubMed ID: 6931470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response of negative symptoms of schizophrenia to neuroleptic treatment.
    Serban G; Siegel S; Gaffney M
    J Clin Psychiatry; 1992 Jul; 53(7):229-34. PubMed ID: 1639741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clopenthixol and flupenthixol depot preparations in outpatient schizophrenics. II. Factor analysis of the CPRS sub-scale for schizophrenia.
    Dencker SJ; Frankenberg K; Hansen V; Malm U
    Acta Psychiatr Scand Suppl; 1980; 279():29-40. PubMed ID: 6931471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Do schizophrenics well adapted in the community need neuroleptics? A depot neuroleptic withdrawal study.
    Dencker SJ; Lepp M; Malm U
    Acta Psychiatr Scand Suppl; 1980; 279():64-76. PubMed ID: 6105763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clopenthixol and flupenthixol depot preparations in outpatient schizophrenics. IV. Serum levels and clinical outcome.
    Dencker SJ; Malm U; Jørgensen A; Overø KF
    Acta Psychiatr Scand Suppl; 1980; 279():55-63. PubMed ID: 6931473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of anticholinergics on positive and negative symptoms in schizophrenia.
    Tandon R; DeQuardo JR; Goodson J; Mann NA; Greden JF
    Psychopharmacol Bull; 1992; 28(3):297-302. PubMed ID: 1480733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Positive and negative symptoms in chronic schizophrenic patients under maintenance therapy with flupenthixol decanoate for a twelve month perioid].
    Pach J; Finkbeiner T; Glaser T; Haug J; Osterheider M; Tegeler J
    Fortschr Neurol Psychiatr; 1998 Oct; 66(10):442-9. PubMed ID: 9825249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Incidence of the deficit form in refractory schizophrenia].
    Samuelian JC
    Encephale; 1996 Jun; 22 Spec No 2():19-23. PubMed ID: 8767037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of flupentixol and risperidone in chronic schizophrenia with predominantly negative symptoms.
    Ruhrmann S; Kissling W; Lesch OM; Schmauss M; Seemann U; Philipp M
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1012-22. PubMed ID: 17412473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Comparative effectiveness of flupenthixol and risperidone on negative symptoms of schizophrenia].
    Philipp M; Lesch OM; Schmauss M; Dose M; Glaser T
    Psychiatr Prax; 2003 May; 30 Suppl 2():S94-6. PubMed ID: 14509050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clozapine and treatment of negative symptoms].
    Lançon C; Farisse J; Llorca PM
    Encephale; 1997 Sep; 23 Spec No 4():7-11. PubMed ID: 9417403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Profile of the action of neuroleptics in deficit schizophrenia].
    Vanelle JM
    Encephale; 1996 Jun; 22 Spec No 2():33-9. PubMed ID: 8767040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The risk of rehospitalisation during therapy with atypical and typical neuroleptics--a contribution to differential indication].
    Müller P; Nerenz H; Schaefer E
    Psychiatr Prax; 2002 Oct; 29(7):388-91. PubMed ID: 12378421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Double-blind comparison of 2 depot neuroleptics (perphenazine enanthate and flupentixol decanoate) in chronic schizophrenia (author's transl)].
    Eufe R; Wegener G
    Nervenarzt; 1979 Aug; 50(8):534-9. PubMed ID: 394015
    [No Abstract]   [Full Text] [Related]  

  • 16. [Quality of life and therapeutic result in outpatients with schizophrenia under flupenthixol treatment].
    Kühn KU; Quednow BB; Landen H; Riedel M; Thiel M
    Fortschr Neurol Psychiatr; 2004 Jul; 72(7):397-403. PubMed ID: 15252753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapy with neuroleptics. Clinical and pharmacokinetic aspects with a particular view to depot preparations.
    Knudsen P
    Acta Psychiatr Scand Suppl; 1985; 322():51-75. PubMed ID: 2866666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short-term effect of combined ECT and neuroleptic therapy in treatment-resistant schizophrenia.
    Chanpattana W; Chakrabhand ML; Kongsakon R; Techakasem P; Buppanharun W
    J ECT; 1999 Jun; 15(2):129-39. PubMed ID: 10378152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The decanoates of flupenthixol and clopenthixol in the treatment of chronic schizophrenic in-patients. Implications for community psychiatry.
    Martyns-Yellowe IS
    West Afr J Med; 1993; 12(2):110-3. PubMed ID: 8104468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Empirical evaluation of the factorial structure of clinical symptoms in schizophrenia: effects of typical neuroleptics on the brief psychiatric rating scale.
    Harvey PD; Davidson M; White L; Keefe RS; Hirschowitz J; Mohs RC; Davis KL
    Biol Psychiatry; 1996 Oct; 40(8):755-60. PubMed ID: 8894068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.